Eupraxia Pharmaceuticals(EPRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

EPRX Eupraxia Pharmaceuticals

Market Closed 06-12 16:00:00 EDT

6.04

+0.01

+0.17%

盘后6.04

+0.000.00%

17:28 EDT

High6.20	Low5.96	Vol141.12K
Open6.06	D1 Closing6.03	Amplitude3.98%
Mkt Cap394.57M	Tradable Cap303.94M	Total Shares65.33M
T/O857.57K	T/O Rate0.28%	Tradable Shares50.32M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"EPRX","market":"US","secType":"STK","nameCN":"Eupraxia Pharmaceuticals","latestPrice":6.04,"timestamp":1781294400000,"preClose":6.03,"halted":0,"volume":141122,"hourTrading":{"tag":"盘后","latestPrice":6.04,"preClose":6.04,"latestTime":"17:28 EDT","volume":2932,"amount":17709.694,"timestamp":1781299734340,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.0016583747927031154,"floatShares":50321200,"shares":65326899,"eps":-1.0088483,"marketStatus":"Market Closed","change":0.01,"latestTime":"06-12 16:00:00 EDT","open":6.06,"high":6.2,"low":5.96,"amount":857565.7948179999,"amplitude":0.039801,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.0088483,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1781510400000},"marketStatusCode":7,"adr":0,"listingDate":1712289600000,"exchange":"NASDAQ","adjPreClose":6.03,"postHourTrading":{"tag":"盘后","latestPrice":6.04,"preClose":6.04,"latestTime":"17:28 EDT","volume":2932,"amount":17709.694,"timestamp":1781299734340,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.4542504906406152},"requestUrl":"/m/hq/s/EPRX/tweets","defaultTab":"tweets","newsList":[{"id":"2639167498","title":"Eupraxia Pharmaceuticals Sets June 18, 2026 Virtual AGM and Files May Form 6-K","url":"https://stock-news.laohu8.com/highlight/detail?id=2639167498","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639167498?lang=en_us&edition=fundamental","pubTime":"2026-05-30 02:47","pubTimestamp":1780080439,"startTime":"0","endTime":"0","summary":"Eupraxia Pharmaceuticals ( ($TSE:EPRX) ) has issued an update. Eupraxia Pharmaceuticals Inc. has filed a Form 6-K for May 2026, detailing materials...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/eupraxia-pharmaceuticals-sets-june-18-2026-virtual-agm-and-files-may-form-6-k?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/eupraxia-pharmaceuticals-sets-june-18-2026-virtual-agm-and-files-may-form-6-k?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4195","BK4229","AGM","BK4585","ARKG","BK4588","BK4544","EPRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639745576","title":"Eupraxia Pharmaceuticals Confirms Mailing of 2026 Proxy Materials to Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2639745576","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639745576?lang=en_us&edition=fundamental","pubTime":"2026-05-30 02:27","pubTimestamp":1780079257,"startTime":"0","endTime":"0","summary":"Eupraxia Pharmaceuticals ( ($TSE:EPRX) ) has shared an update. Eupraxia Pharmaceuticals Inc. reported on May 28, 2026 that it has filed a Form 6-K ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/eupraxia-pharmaceuticals-confirms-mailing-of-2026-proxy-materials-to-shareholders?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/eupraxia-pharmaceuticals-confirms-mailing-of-2026-proxy-materials-to-shareholders?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["UYM","BK4139","EPRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639161145","title":"Eupraxia Pharmaceuticals to Showcase Pipeline at Jefferies Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2639161145","media":"TIPRANKS","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639161145?lang=en_us&edition=fundamental","pubTime":"2026-05-29 05:38","pubTimestamp":1780004312,"startTime":"0","endTime":"0","summary":"The latest update is out from Eupraxia Pharmaceuticals ( ($TSE:EPRX) ). On May 28, 2026, Eupraxia Pharmaceuticals said its management team will pre...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/eupraxia-pharmaceuticals-to-showcase-pipeline-at-jefferies-global-healthcare-conference?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/eupraxia-pharmaceuticals-to-showcase-pipeline-at-jefferies-global-healthcare-conference?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBI","LU0128526141.USD","BK4588","BK4139","HCSG","XLV","LABU","LU0029874061.USD","BK4585","BK4581","EPRX","BK4137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638469817","title":"Eupraxia Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2638469817","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638469817?lang=en_us&edition=fundamental","pubTime":"2026-05-28 20:00","pubTimestamp":1779969600,"startTime":"0","endTime":"0","summary":"VANCOUVER, British Columbia, May  28, 2026  (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (\"Eupraxia\" or the \"Company\") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/28/3302790/0/en/Eupraxia-Pharmaceuticals-to-Participate-in-the-Jefferies-Global-Healthcare-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EPRX","LU0029874061.USD","BK4139","XBI","LU0128526141.USD","LABU","BK4585","BK4581","XLV","BK4137","BK4588","HCSG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637380942","title":"Stifel Initiates Eupraxia Pharmaceuticals at Buy With CA$34.37 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2637380942","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637380942?lang=en_us&edition=fundamental","pubTime":"2026-05-21 19:06","pubTimestamp":1779361605,"startTime":"0","endTime":"0","summary":"Eupraxia Pharmaceuticals (EPRX) has an average rating of buy and mean price target of CA$21.74, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research fro","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["EPRX","CA","SF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637387730","title":"Eupraxia Pharmaceuticals Inc : Stifel Initiates Coverage With Buy Rating; Target Price $25","url":"https://stock-news.laohu8.com/highlight/detail?id=2637387730","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637387730?lang=en_us&edition=fundamental","pubTime":"2026-05-21 18:58","pubTimestamp":1779361082,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nFWN41Y0FH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["EPRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637780008","title":"Eupraxia Pharmaceuticals initiated with a Buy at Stifel","url":"https://stock-news.laohu8.com/highlight/detail?id=2637780008","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637780008?lang=en_us&edition=fundamental","pubTime":"2026-05-21 04:15","pubTimestamp":1779308141,"startTime":"0","endTime":"0","summary":"Stifel initiated coverage of Eupraxia Pharmaceuticals (EPRX) with a Buy rating and $25 price target Eupraxia is validating its Diffusphere platform...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/eupraxia-pharmaceuticals-initiated-with-a-buy-at-stifel-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/eupraxia-pharmaceuticals-initiated-with-a-buy-at-stifel-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EPRX","SF","BK4139","BK4127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635260722","title":"Eupraxia Pharmaceuticals Reports Stronger Balance Sheet but Wider Q1 2026 Loss in Form 6-K Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2635260722","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635260722?lang=en_us&edition=fundamental","pubTime":"2026-05-13 06:45","pubTimestamp":1778625904,"startTime":"0","endTime":"0","summary":"An update from Eupraxia Pharmaceuticals ( ($TSE:EPRX) ) is now available. Eupraxia Pharmaceuticals filed a Form 6-K for May 2026, providing unaudit...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/eupraxia-pharmaceuticals-reports-stronger-balance-sheet-but-wider-q1-2026-loss-in-form-6-k-filing?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/eupraxia-pharmaceuticals-reports-stronger-balance-sheet-but-wider-q1-2026-loss-in-form-6-k-filing?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EPRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635226463","title":"Eupraxia Pharmaceuticals reports Q1 net loss ($12.7M) vs. ($6.8M) last year","url":"https://stock-news.laohu8.com/highlight/detail?id=2635226463","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635226463?lang=en_us&edition=fundamental","pubTime":"2026-05-13 06:31","pubTimestamp":1778625086,"startTime":"0","endTime":"0","summary":"The Company had cash and cash equivalents of $58.5M and short-term investments of $80.4M as of March 31, up from a cash balance of $80.6M at the en...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/eupraxia-pharmaceuticals-reports-q1-net-loss-12-7m-vs-6-8m-last-year-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/eupraxia-pharmaceuticals-reports-q1-net-loss-12-7m-vs-6-8m-last-year-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EPRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635223511","title":"Eupraxia Pharmaceuticals Q1 EPS $(0.23) Misses $(0.22) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2635223511","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635223511?lang=en_us&edition=fundamental","pubTime":"2026-05-13 05:08","pubTimestamp":1778620104,"startTime":"0","endTime":"0","summary":"Eupraxia Pharmaceuticals (NASDAQ:EPRX) reported quarterly losses of $(0.23) per share which missed the analyst consensus estimate of $(0.22) by 4.55 percent. This is a 9.52 percent decrease over losses of $(0.21) per","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52509029/eupraxia-pharmaceuticals-q1-eps-0-23-misses-0-22-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Eupraxia Pharmaceuticals Q1 EPS $(0.23) Misses $(0.22) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EPRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635223517","title":"Eupraxia Pharmaceuticals Reports First Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2635223517","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635223517?lang=en_us&edition=fundamental","pubTime":"2026-05-13 05:00","pubTimestamp":1778619600,"startTime":"0","endTime":"0","summary":"Robust response in highest dose cohort after 36 weeks following a single treatment of EP-104GI Completion of a $63.2 million public offering to enable clinical trials of EP-104GI in additional indicat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/12/3293518/0/en/Eupraxia-Pharmaceuticals-Reports-First-Quarter-2026-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EPRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633914036","title":"Eupraxia Pharmaceuticals Reports EREFS Data from its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis at Digestive Disease Week (DDW)","url":"https://stock-news.laohu8.com/highlight/detail?id=2633914036","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633914036?lang=en_us&edition=fundamental","pubTime":"2026-05-05 19:00","pubTimestamp":1777978800,"startTime":"0","endTime":"0","summary":"EREFS is a standardized visual scoring system that gastroenterologists use when performing an endoscopy in EoE patients to assess the severity of inflammation and fibrosis in the esophagus EREFS data ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/05/3287509/0/en/Eupraxia-Pharmaceuticals-Reports-EREFS-Data-from-its-Ongoing-Phase-1b-2a-RESOLVE-Trial-in-Eosinophilic-Esophagitis-at-Digestive-Disease-Week-DDW.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EPRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633892957","title":"Eupraxia Pharmaceuticals Price Target Maintained With a $11.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2633892957","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633892957?lang=en_us&edition=fundamental","pubTime":"2026-05-05 00:58","pubTimestamp":1777913880,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/EPRX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 04, 2026 12:58 ET (16:58 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EPRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632548079","title":"H.C. Wainwright Remains a Buy on Eupraxia Pharmaceuticals (EPRX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2632548079","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632548079?lang=en_us&edition=fundamental","pubTime":"2026-05-04 23:15","pubTimestamp":1777907716,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Brandon Folkes reiterated a Buy rating on Eupraxia Pharmaceuticals today and set a price target of $11.00. According to Tip...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-remains-a-buy-on-eupraxia-pharmaceuticals-eprx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/h-c-wainwright-remains-a-buy-on-eupraxia-pharmaceuticals-eprx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EPRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632400616","title":"Eupraxia Pharmaceuticals Appoints Dr. Jeymi Tambiah as Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2632400616","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632400616?lang=en_us&edition=fundamental","pubTime":"2026-05-02 05:05","pubTimestamp":1777669500,"startTime":"0","endTime":"0","summary":"VANCOUVER, British Columbia, May  01, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (\"Eupraxia\" or the \"Company\") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging i","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/01/3286252/0/en/Eupraxia-Pharmaceuticals-Appoints-Dr-Jeymi-Tambiah-as-Chief-Medical-Officer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EPRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629045996","title":"Eupraxia Pharmaceuticals Price Target Maintained With a $11.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2629045996","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629045996?lang=en_us&edition=fundamental","pubTime":"2026-04-22 19:48","pubTimestamp":1776858480,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/EPRX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 22, 2026 07:48 ET (11:48 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EPRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629100040","title":"Eupraxia Pharmaceuticals to Present at Digestive Disease Week Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2629100040","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629100040?lang=en_us&edition=fundamental","pubTime":"2026-04-22 19:00","pubTimestamp":1776855600,"startTime":"0","endTime":"0","summary":"VANCOUVER, British Columbia, April  22, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (\"Eupraxia\" or the \"Company\") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/22/3278788/0/en/Eupraxia-Pharmaceuticals-to-Present-at-Digestive-Disease-Week-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EPRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629099184","title":"Craig-Hallum Sticks to Their Buy Rating for Eupraxia Pharmaceuticals (EPRX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2629099184","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629099184?lang=en_us&edition=fundamental","pubTime":"2026-04-22 12:47","pubTimestamp":1776833228,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Albert Lowe from Craig-Hallum maintained a Buy rating on Eupraxia Pharmaceuticals. The company’s shares closed yest...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/craig-hallum-sticks-to-their-buy-rating-for-eupraxia-pharmaceuticals-eprx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/craig-hallum-sticks-to-their-buy-rating-for-eupraxia-pharmaceuticals-eprx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EPRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629033663","title":"Eupraxia Pharmaceuticals Reports Positive Nine-Month Tissue Health and Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2629033663","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629033663?lang=en_us&edition=fundamental","pubTime":"2026-04-21 19:00","pubTimestamp":1776769200,"startTime":"0","endTime":"0","summary":"This is the first release of 36-week symptom response & tissue health data for the highest dose (Cohort 9) from the dose escalation portion of Eupraxia’s RESOLVE trial.At 36 weeks, patients in Cohort ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/21/3277764/0/en/Eupraxia-Pharmaceuticals-Reports-Positive-Nine-Month-Tissue-Health-and-Symptom-Data-from-the-Highest-Dose-Cohort-in-its-Ongoing-Phase-1b-2a-RESOLVE-Trial-in-Eosinophilic-Esophagiti.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","EPRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627473562","title":"Eupraxia Pharmaceuticals to Highlight Drug-Delivery Pipeline at April Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2627473562","media":"TIPRANKS","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627473562?lang=en_us&edition=fundamental","pubTime":"2026-04-15 08:08","pubTimestamp":1776211739,"startTime":"0","endTime":"0","summary":"Eupraxia Pharmaceuticals ( ($TSE:EPRX) ) has issued an announcement. Eupraxia Pharmaceuticals, a clinical-stage biotech specializing in locally del...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/eupraxia-pharmaceuticals-to-highlight-drug-delivery-pipeline-at-april-investor-conferences?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/eupraxia-pharmaceuticals-to-highlight-drug-delivery-pipeline-at-april-investor-conferences?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","EPRX"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.eupraxiapharma.com","stockEarnings":[{"period":"1week","weight":0.0151},{"period":"1month","weight":-0.2},{"period":"3month","weight":-0.1793},{"period":"6month","weight":-0.0367},{"period":"1year","weight":0.5547},{"period":"ytd","weight":-0.2}],"compareEarnings":[{"period":"1week","weight":0.0057},{"period":"1month","weight":-0.0008},{"period":"3month","weight":0.12},{"period":"6month","weight":0.088},{"period":"1year","weight":0.2286},{"period":"ytd","weight":0.0877}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidate is EP-104IAR, which is in a Phase II clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis and eosinophilic esophagitis, as well as under development for treating canine osteoarthritis. Its products in development also include EP-201, an antibiotic for post-surgical site infections; and EP-105, an extended-release post-surgical anesthetic for post-surgical pain. In addition, the company develops product candidates for oncology. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012.Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.","exchange":"NASDAQ","name":"Eupraxia Pharmaceuticals","nameEN":"Eupraxia Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Eupraxia Pharmaceuticals(EPRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Eupraxia Pharmaceuticals(EPRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Eupraxia Pharmaceuticals,EPRX,Eupraxia Pharmaceuticals股票,Eupraxia Pharmaceuticals股票老虎,Eupraxia Pharmaceuticals股票老虎国际,Eupraxia Pharmaceuticals行情,Eupraxia Pharmaceuticals股票行情,Eupraxia Pharmaceuticals股价,Eupraxia Pharmaceuticals股市,Eupraxia Pharmaceuticals股票价格,Eupraxia Pharmaceuticals股票交易,Eupraxia Pharmaceuticals股票购买,Eupraxia Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Eupraxia Pharmaceuticals(EPRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Eupraxia Pharmaceuticals(EPRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}